18F-FDG PET with or without CT in the diagnosis of extrahepatic metastases or local residual/recurrent hepatocellular carcinoma. Issue 34 (August 2018)

• Record Type: Journal Article
• Authors: Liao, Xiaoli; Wei, Junbao; Li, Yongqiang; Zhong, Jianhong; Liu, Zhihui; Liao, Sina; Li, Qian; Wei, Changyuan
• Other Names: Yi. Kou section editor.
• Is Part Of: Medicine. Volume 97:Issue 34(2018)
• Publication Date: 2018-08
• Subjects: 18-fluorodeoxyglucose -- hepatocellular carcinoma -- meta-analysis -- positron emission tomography/computed tomography -- recurrent; Medicine -- Periodicals; Medicine -- Periodicals; Médecine -- Périodiques; Geneeskunde; Medicine; Periodicals; Periodicals; 610.5
• DOI: 10.1097/MD.0000000000011970
• Languages: English
• ISSNs: 0025-7974

Abstract

Abstract : Abstract: The aim of the present study was to meta-analyze the literature on the diagnostic value of 18-fluorodeoxyglucose ( 18 F-FDG) positron emission tomography (PET) with or without computed tomography (CT) in detecting extrahepatic metastases or local residual/recurrent hepatocellular carcinoma (HCC). Systematic review of literature in MEDLINE, Embase, and Cochrane databases was conducted in March 2017, and relevant studies analyzing the diagnostic performance of 18 F-FDG PET with or without CT were meta-analyzed. Meta-analysis was carried out on data from 11 studies involving 572 patients. 18 F-FDG PET, with or without CT, showed pooled sensitivity of 64% and pooled specificity of 95%. Pooled sensitivity was similar with CT (74%) or without (52%; P = .279). Similarly, pooled specificity was comparable with CT (93%) or without 95% ( P = .481). 18 F-FDG PET, with or without CT, shows relatively low sensitivity but high specificity for diagnosing extrahepatic metastases or local residual/recurrent HCC. Adding CT to 18 F-FDG PET may improve diagnostic performance, but the available evidence suggests that the improvement is not statistically significant. Abstract : Supplemental Digital Content is available in the text